ArticleBritish journal of cancer2010
Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Proteomic Profiling of EUS-FNA Samples Differentiates Pancreatic Adenocarcinoma from Mass-Forming Chronic Pancreatitis.Biomedicines · 2025Article
- Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.Journal of gastroenterology · 2024Article
- Histone Modification Screening using Liquid Chromatography, Trapped Ion Mobility Spectrometry, and Time-Of-Flight Mass Spectrometry.Journal of visualized experiments : JoVE · 2024Article
- Review
- Proteomics-Driven Biomarkers in Pancreatic Cancer.Proteomes · 2023Review
- Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.Scientific reports · 2022Article
- Apolipoprotein A-II, a Player in Multiple Processes and Diseases.Biomedicines · 2022Review
- Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling.Cancer cell international · 2021Article
- Soluble stroma-related biomarkers of pancreatic cancer.EMBO molecular medicine · 2018Article
- Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro.Journal of biochemical and molecular toxicology · 2018Article
- Article
- Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer.Biomarkers in medicine · 2016Review
- Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo.PloS one · 2016Article
- Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models.British journal of cancer · 2015Article
- Pancreatic Cancer: a Challenge to Cure.The Indian journal of surgery · 2015Article
- Identification of apolipoprotein C-I as a potential Wilms' tumor marker after excluding inflammatory factors.International journal of molecular sciences · 2014Article
- Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Molecular cancer · 2014Article
- Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.Journal of proteome research · 2014Article
- SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe serum/plasma proteome was explored for biomarkers to improve the diagnostic ability of CA19-9 in pancreatic adenocarcinoma (PC).
methodsA Training Set of serum samples from 20 resectable and 18 stage IV PC patients, 54 disease controls (DCs) and 68 healthy volunteers (HVs) were analysed by surface-enhanced laser desorption and ionisation time-of-flight mass spectrometry (SELDI-TOF MS). The resulting protein panel was validated on 40 resectable PC, 21 DC and 19 HV plasma samples (Validation-1 Set) and further by ELISA on 33 resectable PC, 28 DC and 18 HV serum samples (Validation-2 Set). Diagnostic panels were derived using binary logistic regression incorporating internal cross-validation followed by receiver operating characteristic (ROC) analysis.
resultsA seven-protein panel from the training set PC vs DC and from PC vs HV samples gave the ROC area under the curve (AUC) of 0.90 and 0.90 compared with 0.87 and 0.91 for CA19-9. The AUC was greater (0.97 and 0.99, P<0.05) when CA19-9 was added to the panels and confirmed on the validation-1 samples. A simplified panel of apolipoprotein C-I (ApoC-I), apolipoprotein A-II (ApoA-II) and CA19-9 was tested on the validation-2 set by ELISA, in which the ROC AUC was greater than that of CA19-9 alone for PC vs DC (0.90 vs 0.84) and for PC vs HV (0.96 vs 0.90).
conclusionsA simplified diagnostic panel of CA19-9, ApoC-I and ApoA-II improves the diagnostic ability of CA19-9 alone and may have clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.